Atlas Trials

Stemline Therapeutics, Inc.

20 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Stemline Therapeutics, Inc.

RecordFirmDate
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer (NCT07766018)Stemline Therapeutics, Inc.2026-08-01
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer (NCT07226427)Stemline Therapeutics, Inc.2026-01-10
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (NCT06456463)Stemline Therapeutics, Inc.2025-01-14
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (NCT06638307)Stemline Therapeutics, Inc.2024-10-25
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (NCT06492616)Stemline Therapeutics, Inc.2024-09-27
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function (NCT06126575)Stemline Therapeutics, Inc.2023-03-13
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer (NCT05386108)Stemline Therapeutics, Inc.2022-08-31
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors (NCT05382936)Stemline Therapeutics, Inc.2021-03-19
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (NCT03778931)Stemline Therapeutics, Inc.2019-05-10
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer (NCT03088527)Stemline Therapeutics, Inc.2017-10-23

Track Stemline Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.